1-20 of 22
Chris H. Takimoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): PL6-1.
https://doi.org/10.1158/DIAG-10-PL6-1
Published: 15 August 2014
View article titled, Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development
Journal Articles

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Frederico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, Christie Low, Jerry Huang, Margaret Dugan, Kathryn Parker, Eric Walk, Allan van Oosterom, Erika Martinelli, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6364–6372.
https://doi.org/10.1158/1078-0432.CCR-12-1499
Published: 14 November 2012
View article titled, Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
Open the PDF for Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Patricia M. LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan, John Sarantopoulos, Daniel Mulkerin, Stephen I. Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A. Rudek, Chris H. Takimoto, Rachel Neuwirth, Dixie-Lee Esseltine, Percy Ivy
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2954–2963.
https://doi.org/10.1158/1078-0432.CCR-11-2873
Published: 14 May 2012
View article titled, Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432
Open the PDF for Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432 in another window
Journal Articles

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Alain C. Mita, Chris H. Takimoto, Monica Mita, Anthony Tolcher, Kamalesh Sankhala, John Sarantopoulos, Manuel Valdivieso, Leslie Wood, Erik Rasmussen, Yu-Nien Sun, Z. Don Zhong, Michael B. Bass, NgocDiep Le, Patricia LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3044–3056.
https://doi.org/10.1158/1078-0432.CCR-09-3368
Published: 31 May 2010
View article titled, Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
Open the PDF for Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4207–4212.
https://doi.org/10.1158/1078-0432.CCR-08-2429
Published: 15 June 2009
View article titled, A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes

Ricardo M. Attar, Chris H. Takimoto, Marco M. Gottardis
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3251–3255.
https://doi.org/10.1158/1078-0432.CCR-08-1171
Published: 18 May 2009
View article titled, Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
Open the PDF for Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes in another window
Journal Articles

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

Jane E. Latz, Karen Lee Schneck, Kazuhiko Nakagawa, Mary Alice Miller, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (1): 346–354.
https://doi.org/10.1158/1078-0432.CCR-08-0791
Published: 31 December 2008
View article titled, Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients
Open the PDF for Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients in another window
Journal Articles

Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function

Chris H. Takimoto, Martin A. Graham, Graham Lockwood, Chee M. Ng, Andrew Goetz, Dennis Greenslade, Scot C. Remick, Sunil Sharma, Sridhar Mani, Ramesh K. Ramanathan, Timothy W. Synold, James H. Doroshow, Anne Hamilton, Daniel L. Mulkerin, Percy Ivy, Merrill J. Egorin, Jean L. Grem
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (16): 4832–4839.
https://doi.org/10.1158/1078-0432.CCR-07-0475
Published: 15 August 2007
View article titled, Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function
Open the PDF for Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function in another window
Journal Articles

Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study

Timothy W. Synold, Chris H. Takimoto, James H. Doroshow, David Gandara, Sridhar Mani, Scot C. Remick, Daniel L. Mulkerin, Anne Hamilton, Sunil Sharma, Ramesh K. Ramanathan, Heinz Josef Lenz, Martin Graham, Jeffrey Longmate, Bennett M. Kaufman, Percy Ivy
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3660–3666.
https://doi.org/10.1158/1078-0432.CCR-06-2385
Published: 15 June 2007
View article titled, Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Chris H. Takimoto, Lisa A. Hammond-Thelin, Jane E. Latz, Leonardo Forero, Muralidhar Beeram, Bahram Forouzesh, Johann de Bono, Anthony W. Tolcher, Amita Patnaik, Pamela Monroe, Leslie Wood, Karen B. Schneck, Romnee Clark, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-06-2393
Published: 01 May 2007
View article titled, Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
Open the PDF for Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer in another window
Journal Articles

Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer

Christopher J. Sweeney, Chris H. Takimoto, Jane E. Latz, Sharyn D. Baker, Daryl J. Murry, James H. Krull, Karen Fife, Linda Battiato, Ann Cleverly, Ajai K. Chaudhary, Tuhin Chaudhuri, Alan Sandler, Alain C. Mita, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (2): 536–542.
https://doi.org/10.1158/1078-0432.CCR-05-1834
Published: 20 January 2006
View article titled, Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer
Open the PDF for Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer in another window
Journal Articles

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

Lillian L. Siu, Ahmad Awada, Chris H. Takimoto, Martine Piccart, Brian Schwartz, Tom Giannaris, Chetan Lathia, Oana Petrenciuc, Malcolm J. Moore
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 144–151.
https://doi.org/10.1158/1078-0432.CCR-05-1571
Published: 05 January 2006
View article titled, Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Open the PDF for Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer in another window
Journal Articles

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

Alejandro D. Ricart, Lisa A. Hammond, John G. Kuhn, Chris H. Takimoto, Andrew Goetz, Bahram Forouzesh, Leonardo Forero, Jose L. Ochoa-Bayona, Kristin Berg, Anthony W. Tolcher, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8728–8736.
https://doi.org/10.1158/1078-0432.CCR-05-1572
Published: 16 December 2005
View article titled, Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

James A. Posey, III, M. Wasif Saif, Ronda Carlisle, Andrew Goetz, Jinee Rizzo, Suzanne Stevenson, Marc S. Rudoltz, Joseph Kwiatek, Paul Simmons, Eric K. Rowinsky, Chris H. Takimoto, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7866–7871.
https://doi.org/10.1158/1078-0432.CCR-05-0783
Published: 08 November 2005
View article titled, Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas in another window
Journal Articles

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert Gazak, John T. Callaghan, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5540–5549.
Published: 03 December 2003
View article titled, A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies

Amita Patnaik, S. Gail Eckhardt, Elzbieta Izbicka, Anthony A. Tolcher, Lisa A. Hammond, Chris H. Takimoto, Garry Schwartz, Heather McCreery, Andrew Goetz, Masataka Mori, Kazutoyo Terada, Lou Gentner, Mary-Ellen Rybak, Henry Richards, Steven Zhang, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 4761–4771.
Published: 27 October 2003
View article titled, A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies
Open the PDF for A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor

Desirée Hao, Lisa A. Hammond, S. Gail Eckhardt, Amita Patnaik, Chris H. Takimoto, Garry H. Schwartz, Andrew D. Goetz, Anthony W. Tolcher, Heather A. McCreery, Khalid Mamun, Jon I. Williams, Kenneth J. Holroyd, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2465–2471.
Published: 01 July 2003
View article titled, A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor
Open the PDF for A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor in another window
Journal Articles

A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies

Mitchell A. Garrison, Lisa A. Hammond, Charles E. Geyer, Jr., Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, Jose A. Figueroa, Murray Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2527–2537.
Published: 01 July 2003
View article titled, A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients

Jean L. Grem, Nancy Harold, Bruce Keith, Alice P. Chen, Viven Kao, Chris H. Takimoto, J. Michael Hamilton, Janet Pang, Marie Pace, Gada B. Jasser, Mary G. Quinn, Brian P. Monahan
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2149–2156.
Published: 01 July 2002
View article titled, A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients
Open the PDF for A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients in another window
Journal Articles

Why Drugs Fail: Of Mice and Men Revisited

Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (2): 229–230.
Published: 01 February 2001
View article titled, Why Drugs Fail: Of Mice and Men Revisited
Open the PDF for Why Drugs Fail: Of Mice and Men Revisited in another window